Briefs
Through the 2020s, life sciences leaders have dealt with one challenge after another. The shock of the COVID-19 pandemic. Sticky inflation. Return-to-office mandates. The intense pressure to perform in the face of disruptive challenges has proven constant.
For commercial learning and development, also known as commercial L&D, this has presented new roadblocks and innovations alike, making data more important than ever to navigate a rapidly changing industry. That’s why TGaS Advisors, a Division of Trinity Life Sciences, in partnership with…
Read Now
Briefs
How are Commercial, Medical and Market Access organizations evolving to develop capabilities and accelerate innovation in 2025 and beyond?
Executive leaders are focused on making informed organizational decisions to propel the evolution of capabilities in this rapidly changing global economy. As you strategize to optimize structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ 2025 Spring Summit.
Complete the form below to access the advisory brief.
By submitting this form,…
Read Now
Briefs
Trinity Life Sciences, a leader in global life sciences commercialization solutions, released its third annual TGaS Digital Marketing Competency Report assessing 150+ biopharma brands through the lens of digital marketing patient/caregiver experiences. The study evaluates the brands across five categories and more than 100 characteristics to understand each one’s digital marketing presence and establish a brand digital competency ranking.
Learn what sets some brands apart from others. To download the excerpt of the report with the ranking of all 150+…
Read Now
Briefs
The healthcare industry has long been known for its significant environmental impact, including contributing ~5% of total global emissions. As awareness of this impact has increased, life sciences companies are now actively committing to climate resilience and environmental sustainability through various initiatives, including net-zero commitments.
Trinity Life Sciences has identified several recent trends driving this shift including increasing Health Technology Assessment (HTA) requirements, investment reporting, patient and healthcare provider (HCP) demands for greener options, heightened awareness of waste and a…
Read Now
Briefs
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 and all new medicines from 2030.
The JCA process will run parallel to European Medicines Agency (EMA) regulatory evaluation and will involve submission of a…
Read Now
Briefs
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute for Health and Care Excellence (NICE) assessments in the U.K., public reports on a product’s value are bound to influence discussions and negotiations between payers…
Read Now
Briefs
Improving partnerships is a crucial aspect of successful organizations. However, many companies face challenges in aligning their Commercial Operations and Information Technology teams. These conflicts often lead to inefficiencies in processes, resources and functionality, which ultimately impact the overall capabilities of the organization. To address these challenges, companies have implemented various strategies to enhance collaboration and alignment. Our observation suggests that the key to resolving these issues lies in fostering strong relationships between the teams.
During our conversations with industry…
Read Now
Briefs
The “molecular optimizer” archetype is a strategy utilized by first-launch companies to optimize existing molecules when developing their first product. Companies using this approach tend to be small and emerging biotech firms that are seeking a foothold to enter the market.
The primary benefit of this approach is that the method offers a higher probability of regulatory approval and streamlines the manufacturer’s path to commercialization. With these benefits come some challenges related to access and pricing of a new product…
Read Now
Briefs
Highlights from TGaS Advisors’ Fall Summit
How are Biopharmaceutical organizations evolving to develop capabilities and propel innovation for 2024 and beyond?
Executive leaders in Commercial Operations, Medical Affairs and Market Access are focused on making informed decisions to propel the evolution of their organizations in this rapidly changing global economy. As you strategize to accelerate optimizing structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ Fall Summit.…
Read Now
Briefs
Rare diseases present unique challenges to companies looking to commercialize treatments.
Although there is vast potential in rare disease, each space is different and unique.
Companies must effectively address challenges around identifying and treating patients—as well as providing long-term support. It is critical that companies understand the nuances in each disease.
Keeping a patient-first mentality, advancing patients’ needs and providing excellent support services are mission-critical for life sciences companies touching rare disease. However, lack of disease awareness and unclear referral…
Read Now
